|
1
|
Crew KD and Neugut AI: Epidemiology of
gastric cancer. World J Gastroenterol. 12:354–362. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Siegel R, Ward E, Murray T, Xu J
and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin. 57:43–66.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yoo CH, Noh SH, Shin DW, Choi SH and Min
JS: Recurrence following curative resection for gastric carcinoma.
Br J Surg. 87:236–242. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen CN, Lin JJ, Chen JJ, Lee PH, Yang CY,
Kuo ML, Chang KJ and Hsieh FJ: Gene expression profile predicts
patient survival of gastric cancer after surgical resection. J Clin
Oncol. 23:7286–7295. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jian P, Yanfang T, Zhuan Z, Jian W,
Xueming Z and Jian N: MMP28 (epilysin) as a novel promoter of
invasion and metastasis in gastric cancer. BMC Cancer. 11:2002011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
You Y, Yang W, Wang Z, Zhu H, Li H, Lin C
and Ran Y: Promoter hypermethylation contributes to the frequent
suppression of the CDK10 gene in human nasopharyngeal carcinomas.
Cell Oncol (Dordr). 36:323–331. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
You Y, Li H, Qin X, Zhang Y, Song W, Ran Y
and Gao F: Decreased CDK10 expression correlates with lymph node
metastasis and predicts poor outcome in breast cancer patients-a
short report. Cell Oncol (Dordr). 38:485–491. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hong CQ, Zhang F, You YJ, Qiu WL, Giuliano
AE, Cui XJ, Zhang GJ and Cui YK: Elevated C1orf63 expression is
correlated with CDK10 and predicts better outcome for advanced
breast cancers: A retrospective study. BMC Cancer. 15:5482015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Graña X, Claudio PP, De Luca A, Sang N and
Giordano A: PISSLRE, a human novel CDC2-related protein kinase.
Oncogene. 9:2097–2103. 1994.PubMed/NCBI
|
|
10
|
Brambilla R and Draetta G: Molecular
cloning of PISSLRE, a novel putative member of the cdk family of
protein serine/threonine kinases. Oncogene. 9:3037–3041.
1994.PubMed/NCBI
|
|
11
|
Li S, MacLachlan TK, De Luca A, Claudio
PP, Condorelli G and Giordano A: The cdc-2-related kinase, PISSLRE,
is essential for cell growth and acts in G2 phase of the cell
cycle. Cancer Res. 55:3992–3995. 1995.PubMed/NCBI
|
|
12
|
Iorns E, Turner NC, Elliott R, Syed N,
Garrone O, Gasco M, Tutt AN, Crook T, Lord CJ and Ashworth A:
Identification of CDK10 as an important determinant of resistance
to endocrine therapy for breast cancer. Cancer Cell. 13:91–104.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Khanal P, Yun HJ, Lim SC, Ahn SG, Yoon HE,
Kang KW, Hong R and Choi HS: Proyl isomerase Pin1 facilitates
ubiquitin-mediated degradation of cyclin-dependent kinase 10 to
induce tamoxifen resistance in breast cancer cells. Oncogene.
31:3845–3856. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yu JH, Zhong XY, Zhang WG, Wang ZD, Dong
Q, Tai S, Li H and Cui YF: CDK10 functions as a tumor suppressor
gene and regulates survivability of biliary tract cancer cells.
Oncol Rep. 27:1266–1276. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhong XY, Xu XX, Yu JH, Jiang GX, Yu Y,
Tai S, Wang ZD and Cui YF: Clinical and biological significance of
Cdk10 in hepatocellular carcinoma. Gene. 498:68–74. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
You Y, Yang W, Qin X, Wang F, Li H, Lin C,
Li W, Gu C, Zhang Y and Ran Y: ECRG4 acts as a tumor suppressor and
as a determinant of chemotherapy resistance in human nasopharyngeal
carcinoma. Cell Oncol (Dordr). 38:205–214. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
You Y, Li H, Qin X, Ran Y and Wang F:
Down-regulated ECRG4 expression in breast cancer and its
correlation with tumor progression and poor prognosis-A short
Report. Cell Oncol (Dordr). 39:89–95. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lin C, Xin S, Qin X, Li H, Lin L and You
Y: Zoledronic acid suppresses metastasis of esophageal squamous
cell carcinoma cells through upregulating the tight junction
protein occludin. Cytotechnology. 68:1233–1241. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mahale S, Bharate SB, Manda S, Joshi P,
Jenkins PR, Vishwakarma RA and Chaudhuri B: Antitumour potential of
BPT: A dual inhibitor of cdk4 and tubulin polymerization. Cell
Death Dis. 6:e17432015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
VanArsdale T, Boshoff C, Arndt KT and
Abraham RT: Molecular pathways: Targeting the cyclin D-CDK4/6 axis
for cancer treatment. Clin Cancer Res. 21:2905–2910. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Feng Z, Xu S, Liu M, Zeng YX and Kang T:
Chk1 inhibitor Gö6976 enhances the sensitivity of nasopharyngeal
carcinoma cells to radiotherapy and chemotherapy in vitro and in
vivo. Cancer Lett. 297:190–197. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Guen VJ, Gamble C, Flajolet M, Unger S,
Thollet A, Ferandin Y, Superti-Furga A, Cohen PA, Meijer L and
Colas P: CDK10/cyclin M is a protein kinase that controls ETS2
degradation and is deficient in STAR syndrome. Proc Natl Acad Sci
USA. 110:pp. 19525–19530. 2013; View Article : Google Scholar : PubMed/NCBI
|
